Michael J. Thirman

10.3k total citations · 2 hit papers
90 papers, 4.0k citations indexed

About

Michael J. Thirman is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Michael J. Thirman has authored 90 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Hematology, 41 papers in Molecular Biology and 29 papers in Genetics. Recurrent topics in Michael J. Thirman's work include Acute Myeloid Leukemia Research (52 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Chronic Myeloid Leukemia Treatments (21 papers). Michael J. Thirman is often cited by papers focused on Acute Myeloid Leukemia Research (52 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Chronic Myeloid Leukemia Treatments (21 papers). Michael J. Thirman collaborates with scholars based in United States, France and Canada. Michael J. Thirman's co-authors include Richard A. Larson, Janet D. Rowley, Roger Luo, Hirofumi Kobayashi, Andrew Artz, Federico Simone, Courtney D. DiNardo, Jalaja Potluri, Keith W. Pratz and Brenda Chyla and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Michael J. Thirman

88 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. profile →
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

2024 47 citations Keith W. Pratz, Courtney D. DiNardo et al. Blood profile →

Peers

Countries citing papers authored by Michael J. Thirman

Since Specialization

Citations

This map shows the geographic impact of Michael J. Thirman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Thirman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Thirman more than expected).

Fields of papers citing papers by Michael J. Thirman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Thirman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Thirman. The network helps show where Michael J. Thirman may publish in the future.

Co-authorship network of co-authors of Michael J. Thirman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Thirman. A scholar is included among the top collaborators of Michael J. Thirman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Thirman. Michael J. Thirman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 2024 ·Blood ·Anand Patel, Adam DuVall, Caner Saygin, Howard Weiner, (unknown), (unknown), (unknown), (unknown), Michael W. Drazer, (unknown), Gregory W. Roloff, Satyajit Kosuri, Michael J. Thirman, Richard A. Larson, Olatoyosi Odenike, Theodore Karrison, Wendy Stock	2
2	Impact of F LT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia 2022 ·Clinical Cancer Research ·Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Récher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei	59
3	Safety and Efficacy of Menin Inhibition in Patients (Pts) with MLL-Rearranged and NPM1 Mutant Acute Leukemia: A Phase (Ph) 1, First-in-Human Study of SNDX-5613 (AUGMENT 101) 2021 ·Blood ·Eytan M. Stein, Ibrahim Aldoss, John F. DiPersio, Richard M. Stone, Martha Arellano, Galit Rosen, Michael L. Meyers, Yifan Huang, Steve Smith, Rebecca G. Bagley, Michael J. Thirman, Manish R. Patel, Ghayas C. Issa	41
4	A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia 2018 ·Journal of Hematology & Oncology ·Amy Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A. Larson, Olatoyosi Odenike, Andrew Artz, Michael R. Bishop, Lucy A. Godley, Michael J. Thirman, Satyajit Kosuri, Jane E. Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu	50
5	Regulation of MEIS1 by distal enhancer elements in acute leukemia 2013 ·Leukemia ·(unknown), (unknown), (unknown), Bingjie Li, Joseph J. Kaberlein, (unknown), (unknown), Roger Luo, Jun Ni, Fuhong He, Jun Wu, Ryan J. Mattison, Jing Zhou, (unknown), Shyam Prabhakar, Marcelo A. Nóbrega, Michael J. Thirman	15
6	A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes 2013 ·Bone Marrow Transplantation ·Frederick L. Locke, Rajiv Agarwal, Rangesh Kunnavakkam, Koen van Besien, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, (unknown), Michelle M. Le Beau, Sandeep Gurbuxani, Michael J. Thirman, Dorothy A. Sipkins, Carol White, Andrew Artz, Wendy Stock	17
7	A Manganese Superoxide Dismutase (SOD2)-Mediated Adaptive Response 2012 ·Radiation Research ·David J. Grdina, Jeffrey S. Murley, Richard C. Miller, Helena J. Mauceri, Harold G. Sutton, Michael J. Thirman, Jian Jian Li, Gayle E. Woloschak, Ralph R. Weichselbaum	29
8	Gene Mutations, Epigenetic Dysregulation, and Personalized Therapy in Myeloid Neoplasia: Are We There Yet? 2011 ·Seminars in Oncology ·Olatoyosi Odenike, Michael J. Thirman, Andrew Artz, Lucy A. Godley, Richard A. Larson, Wendy Stock	15
9	PDCD2, a protein whose expression is repressed by BCL6, induces apoptosis in human cells by activation of the caspase cascade 2010 ·Blood Cells Molecules and Diseases ·Beverly W. Baron, Elizabeth Hyjek, (unknown), Michael J. Thirman, Joseph M. Baron	28
10	Dynamic bookmarking of primary response genes by p300 and RNA polymerase II complexes 2009 ·Proceedings of the National Academy of Sciences ·Jung S. Byun, Madeline Wong, Wenwu Cui, Gila Idelman, (unknown), Adriana De Siervi, Sven Bilke, Cynthia M. Haggerty, Audrey Player, Yong Hong Wang, Michael J. Thirman, Joseph J. Kaberlein, Constantinos Petrovas, Richard A. Koup, Dan L. Longo, Keiko Ozato, Kevin Gardner	52
11	Loss of MLL PHD Finger 3 Is Necessary for MLL-ENL–Induced Hematopoietic Stem Cell Immortalization 2008 ·Cancer Research ·Jing Chen, Donna A. Santillan, (unknown), Wei Wei, Roger Luo, Michael J. Thirman, Nancy J. Zeleznik‐Le, Manuel O. Dı́az	45
12	Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products 2008 ·Leukemia & lymphoma ·(unknown), Dorie Sher, Theodore Karrison, Partow Kebriaei, (unknown), Yanming Zhang, (unknown), Andrew Artz, Lucy A. Godley, Olatoyosi Odenike, Elizabeth Rich, Laura C. Michaelis, Michael J. Thirman, Amittha Wickrema, Koen van Besien, Richard A. Larson, Wendy Stock	6
13	Methylation-Independent Silencing of the Tumor Suppressor INK4b (p15) by CBFβ-SMMHC in Acute Myelogenous Leukemia with inv(16) 2007 ·Cancer Research ·Ján Markus, (unknown), Juraj Bies, Naomi Galili, Azra Raza, Michael J. Thirman, Michelle M. Le Beau, Janet D. Rowley, (unknown), Linda Wolff	17
14	Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL‐binding domain 2006 ·The Prostate ·Junghyun Hahn, Wuhan Xiao, Feng Jiang, Federico Simone, Michael J. Thirman, Zhou Wang	13
15	Distinct and Separable Roles of the Complement System in Factor H-Deficient Bone Marrow Chimeric Mice with Immune Complex Disease 2006 ·Journal of the American Society of Nephrology ·Jessy J. Alexander, (unknown), Anthony Chang, Bradley K. Hack, (unknown), Alexander Jacob, Roger Luo, Michael J. Thirman, Mark Haas, Richard J. Quigg	22
16	ELL and EAF1 are Cajal Body Components That Are Disrupted in MLL-ELL Leukemia 2003 ·Molecular Biology of the Cell ·Paul Polak, Federico Simone, Joseph J. Kaberlein, Roger Luo, Michael J. Thirman	37
17	THERAPY-RELATED MYELOID LEUKEMIA 1996 ·Hematology/Oncology Clinics of North America ·Michael J. Thirman, Richard A. Larson	128
18	Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint inAF6 in three patients and in the ML-2 cell line 1996 ·Genes Chromosomes and Cancer ·(unknown), Nancy J. Zeleznik‐Le, Hirofumi Kobayashi, Christine Vignon, (unknown), Michelle M. LeBeau, Michael J. Thirman, Janet D. Rowley	31
19	Abnormalities of Chromosome Band 11q23 and the MLL Gene in Pediatric Myelomonocytic and Monoblastic Leukemias 1995 ·Journal of Pediatric Hematology/Oncology ·José A. Martínez-Climent, Rafael Espinosa, Michael J. Thirman, (unknown), Janet D. Rowley	50
20	DNA rearrangements and altered transcripts of the MLL gene in a human T‐all cell line karpas 45 with a t(X;II) (q13;q23) translocation 1994 ·Genes Chromosomes and Cancer ·Norah R. McCabe, (unknown), Hirofumi Kobayashi, Michael J. Thirman, Heidi J. Gill, Janet D. Rowley, Manuel O. Dı́az	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact